Muscle determination: Another key player in myogenesis?  by Borycki, Anne-Gaelle & Emerson, Charles P.
R620 Dispatch
Muscle determination: Another key player in myogenesis?
Anne-Gaelle Borycki and Charles P. Emerson
The steps that commit multipotential somite cells to
muscle differentiation are being elucidated. Recent
results show that pax3 is an upstream regulator of
myoD, one of the key genes in myogenic lineage
determination.
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During embryonic development, cells are produced with a
progressively more restricted lineage potential. The genetic
mechanisms that control this process of lineage ‘determina-
tion’ are poorly understood, but the discovery of the myoD
gene family opened the door to studies of muscle cell deter-
mination in vertebrate embryos. The first clue that the
myoD genes, which all encode basic helix–loop–helix pro-
teins, are important in myogenic determination came with
the demonstration that they can stably convert non-muscle
cells to skeletal muscle cells in culture [1]. Subsequent
studies have confirmed this conclusion and shown that two
members of the myoD family, myoD itself and myf5, have
early functions in the determination process that commits
multipotential somite cells to the myogenic lineage [2].
The two other myoD genes, myogenin and MRF4, have later
functions in the initiation of myoblast differentiation [3].
An initially puzzling observation was that, in mouse
embryos, myf5 and myoD are activated in somites with dif-
ferent temporal and spatial patterns (Figure 1). The first to
be activated is myf5 — in day 8.0 embryos, signals from the
neighboring neural tube–notochord complex induce myf5
expression in the dorsal-medial somites, in cells that are
progenitors of the trunk and intercostal (epaxial) muscles
[4]. Much later, in day 10.0 embryos, signals from the over-
lying surface ectoderm induce myoD expression in the
dorsal-lateral somites, in cells that are progenitors of body
wall and limb (hypaxial) muscles (Figure 1) [4]. After myf5
and myoD have both been activated, however, most, if not
all, myotomal cells coexpress both genes [4]. This may
account for the apparent redundancy of myf5 and myoD in
the determination of the epaxial and hypaxial myogenic
lineages [2]. Remarkably, double mutant ‘knockout’ mice,
deficient in both myoD and myf5, lack all myogenic progen-
itor cells [2]. In either single mutant, however, muscle dif-
ferentiation is not perturbed at a gross level, although in
myf5 mutant embryos the initial differentiation of epaxial
myotomal muscle is delayed until myoD is activated and
compensates for the loss of myf5 [5,6]. 
Not only are myf5 and myoD essential for muscle forma-
tion, but their expression appears to be the key determi-
native step that commits multipotential somite cells to the
myogenic lineage. This conclusion is based on recent
lineage-tracing experiments using a lacZ reporter gene
cloned into the myf5 locus. In homozygous mutant myf5
embryos, lacZ-expressing somite cells adopt other somite
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Expression of pax3, pax7, myf5 and myoD during mouse embryogenesis.
(a) Colored boxes show the timing of expression of pax7 (purple) [22],
pax3 (red) [11], myf5 (yellow) [9,14,23,24] and myoD (green) [25] in the
neural tube and in somites. Dashed boxes indicate either that expression
level is reducing (pax3) or has not been examined further (myf5).
Significantly, pax7, pax3 and myf5 are transiently expressed, whereas
myoD is expressed throughout development until birth. (b) Expression
domains of pax3 (red), myf5 (yellow) and myoD (green) in the neural
tube and somites of a day 10.5 mouse embryo. NT, neural tube; NC,
notochord; SC, sclerotome; DM, dermomyotome.
lineage fates, expressing sclerotome and dermis genes,
whereas in heterozygotes, all lacZ-expressing cells are
committed to the myogenic lineage [7]. Taking all the evi-
dence together, it is now clear that myoD and myf5 are
redundant genes whose activation — at least in the case of
myf5 — is the determinative step that commits multipo-
tential somite cells to the myogenic lineage.
If myoD and myf5 are the critical determination genes,
then what are the upstream regulatory mechanisms
responsible for their activation in somitic mesoderm? Two
recent papers by Maroto et al. [8] and Tajbakhsh et al. [9]
begin to address this important question by providing
compelling molecular and genetic evidence that pax3 has
dominant myoD-inducing activity in cultured chick cells,
and is an essential upstream gene for myoD expression in
the mouse embryo. These findings also raise intriguing
questions about the specific functions of pax3 in myogenic
determination.
A role for pax3 in body muscle determination
The pax3 gene encodes a member of the subfamily of
homeodomain transcription factors that is defined by the
presence of a ‘paired’ motif [10]. The first sign of pax3
expression is in the neural tube at 8 days of gestation. By
day 8.5, pax3 is expressed in presomitic mesoderm and in
newly formed somites, and its expression becomes pro-
gressively restricted to the dorsal dermomyotome, and
finally to the ventral-lateral part of the dermomyotome in
the population of cells that will migrate to form limb
muscles (Figure 1) [11].
Several spontaneous or X-ray induced pax3 mutant mice,
known as splotch mutants, have been identified. splotch
embryos die before day 15; they display neural defects —
spina bifida, exencephaly and neural crest defects — and
lack limb muscles as a consequence of impaired migration
of the pax3-expressing somite cells in the lateral der-
momyotome [10,12]. splotch mice also display altered
muscle expression of myoD, myf5 and myogenin, in both the
dorsal-medial and ventral-lateral domains of the dermo-
myotome, and lack some of the deep back and ventral
body muscles, further implicating pax3 in at least some
aspects of myogenesis [9]. 
The myogenic function of pax3 was most dramatically
revealed when Tajbakhsh et al. [9] generated splotch/myf5
double mutant embryos. The myf5 deficiency of these
mice forces myogenic determination to occur through the
myoD lineage [6]. Remarkably, Tajbakhsh et al. [9] discov-
ered that the double mutant embryos fail to express myoD
in the somitic mesoderm and completely lack all body
muscles. Despite this severe body muscle phenotype,
head muscles form normally in splotch/myf5 double
mutants, indicating that the head muscles are determined
by a pax3-independent mechanism. 
The absence of body muscles in the splotch/myf5 double
mutants resembles the phenotype of myoD/myf5 double
mutants, consistent with the conclusion that pax3 is an
upstream regulator of myoD. Indeed, myoD expression is
nearly absent in explant co-cultures of somitic mesoderm
and surface ectoderm isolated from splotch mice [9]. These
findings thus provide unexpected, compelling evidence
that pax3 is an essential upstream regulator in the myoD-
dependent body muscle lineage, but not in the head
muscle lineage.
pax3 is a dominant myogenic regulatory gene
Further evidence that pax3 is essential for myoD regulation
comes from the studies of Maroto et al. [8], who expressed
pax3 ectopically in cultured chick embryo tissues using a
retrovirus expression vector. They found that, in pre-
somitic mesoderm explants, pax3 induces myoD expression
and maintains myf5 expression. This fits nicely with the
related finding that myoD is activated in somitic mesoderm
explants that are in contact with the surface ectoderm,
which is known to provide signals for pax3 expression [13].
The more significant and surprising finding, however, is
that 90% of lateral plate mesoderm cells and neural tube
cells infected with a pax3-expressing retrovirus also
express myoD, whereas only 8% of primary dermal fibro-
blasts, and no 10T½ fibroblasts activate myoD in response
to pax3 expression. Curiously, one common feature of the
three tissues affected by pax3 expression — paraxial
mesoderm, neural tube and lateral plate — is that they all
express myf5 at the time of explantation, indicating that
they contain cells with a myogenic potential that is real-
ized when pax3 expression is provided [8,14]. The results
of these chick tissue culture experiments thus strikingly
complement the genetic studies of pax3/myf5 mutant
mice, by showing that pax3 has an essential function in the
activation of myoD — and maintenance of myf5 expression
— in the somitic mesoderm, leading to myogenic determi-
nation and myogenesis.
What is the myogenic function of pax3?
Does pax3 act directly on myogenic determination by
controlling the transcription of myoD (Figure 2a)? Or does
it instead act indirectly, via genes that are essential for
somitic mesoderm functions (Figure 2b)? The most com-
pelling evidence that pax3 has a direct role in myogenic
determination is the finding that ectopic pax3 expression
converts non-muscle neural tube and lateral mesoderm in
tissue culture to muscle [8]. Furthermore, a pax3-express-
ing retrovirus can replace both surface ectoderm and neural
tube/notochord signals for myoD activation in somitic meso-
derm explants [8], showing that pax3 acts downstream of
these myoD-inducing signals. A significant caveat, however,
is that this dominant myogenic activity has only been
demonstrated in tissue culture, which is a notoriously per-
missive environment for skeletal myogenesis [15]. It will
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thus be important to test the myogenic activity of pax3 in
vivo, by determining whether ectopic pax3 expression in
chick or mouse embryos converts non-myogenic cells to
the myogenic lineage. Ectopic pax3 expression has already
been shown to block ventral neural tube differentiation
[16]; it will be of interest to see whether presumptive
neural tube misexpressing pax3 adopts a myogenic fate in
these transgenic animals. 
Another reason to believe that pax3 regulates myogenic
determination is that, in presomitic mesoderm explants
from splotch mouse embryos, myoD is only poorly activated
in the presence of either axial or surface ectoderm signals
[9]. Furthermore, both myf5 and myoD expression, and the
formation of some myf5-dependent muscles, are impaired
in splotch mutant embryos [9]. It is unlikely, however, that
Pax3 protein binds directly to myoD transcriptional
control elements, as the human myoD core enhancer,
which is activated in all epaxial and hypaxial muscles and
head muscles [17], lacks Pax3-binding sites and is not
transactivated by pax3 expression in 10T½ fibroblast cells
(D. Goldhamer, personal communication). So while pax3
may be on the direct pathway for myoD and myf5 regula-
tion, it would have to act on these genes via an inter-
mediary regulator.
Alternatively, pax3 may have an indirect role, regulating
genes involved in early mesoderm and neural tube
functions (Figure 2b). Supporting this model, pax3 is
expressed widely in the dermomyotome and neural tube,
which do not adopt the myogenic fate [11], and splotch
mice have strong neural tube defects [10]. Furthermore,
myoD activation in somitic mesoderm explants from splotch
mice is deficient in response to neural tube/notochord
signals, which regulate myoD indirectly through myf5, as
well as to surface ectoderm signals, which regulate myoD
directly [9]. These observations indicate that pax3 is
required for more general mesoderm functions.
Possible mesoderm functions of pax3 include preserving
dermomyotome integrity, as at early stages in splotch
embryos the epithelial architecture of the dermomyotome
is disrupted, particularly in the lateral region where myoD
is normally activated [18]. Furthermore, splotch mice lack
mesoderm (our unpublished observation), indicating addi-
tional defects in the proliferation and/or survival of somitic
mesoderm in the absence of pax3 activity. That pax3 has a
proliferative function is also suggested by the tumorigenic
activity in rhabdomyosarcomas of fusion proteins encoded
by pax3 joined to the forkhead gene [19]. The mesoderm
phenotype of splotch embryos may be due to a defect in
Figure 2
Models for genetic pathways of muscle
determination and pax3 function. (a) The
direct pathway model for body muscle
formation hypothesizes that Pax3 activates
myoD either directly or via an intermediary
transcription factor. The notochord/neural
tube complex provides signal A responsible
for myf5 activation in somites, and the surface
ectoderm provides signal B, responsible for
pax3 activation [5,8]. myf5 expression in the
dorsal medial domain of the dermomyotome
defines the progenitor cells of epaxial
muscles, and myoD expression in the ventral
lateral domain of the dermomyotome defines
the progenitor cells of hypaxial muscles.
Signal A comprises Sonic hedgehog and a
Wnt; signal B is unknown. (b) The indirect
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assumes that Pax3 is an essential
transcriptional activator for dorsal mesoderm
function, controlling mitotic activity, cell
survival, or cell migration [12,15,26]. In this
model, pax3 expression confers competence
to respond to signals A and C, which induce
myoD and myf5 expression. It remains to be
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signal X activates myf5 and myoD, allowing
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cell migration, as lateral dermomyotome cells fail to
migrate to the limb bud in splotch mutant embryos [12].
Indeed, Pax3 can transcriptionally activate c-met, the
receptor for scatter factor, suggesting that the limb bud, as
well as the body muscle deficiency phenotype seen in
splotch mice may be attributed to the failure of splotch
mesoderm to express c-met [20,21]. 
If this is so, then a strong prediction is that c-met/myf5 and
scatter factor/myf5 double mutant embryos will have similar
body muscle defects to those of splotch/myf5 embryos.
Defects in cell migration could also explain the finding
that somitic mesoderm from splotch mice can differentiate
into muscle when transplanted into the limb bud of a
chick embryo, showing that pax3 is not essential for myo-
genesis, but is required for maintaining more general func-
tions of mesoderm in the somite environment where body
muscles form [12]. This is consistent with the finding that
head muscles form independently of pax3 (Figure 2c).
The available evidence thus favors the conclusion that
pax3 is not directly on the pathway for myogenic determi-
nation, but rather regulates essential, general somatic
mesoderm functions.
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